Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance
Yan He, Can‐Can Zheng, Jing Yang, Shujun Li, Tao‐Yang Xu, Xian Wei, Wen‐You Chen, Zhili Jiang, Jiao-Jiao Xu, Guo‐Geng Zhang, Chao Cheng, Kui-Sheng Chen, Xingyuan Shi, Dajiang Qin, Jinbao Liu, Bin Li
Abstract
Posttranslational modification dramatically enhances protein complexity, but the function and precise mechanism of novel lysine acylation modifications remain unknown. Chemoresistance remains a daunting challenge to successful treatment. We found that lysine butyrylation (Kbu) is specifically upregulated in chemoresistant tumor cells and tissues. By integrating butyrylome profiling and gain/loss-of-function experiments, lysine 754 in HSP90 (HSP90 K754) was identified as a substrate for Kbu. Kbu modification leads to overexpression of HSP90 in esophageal squamous cell carcinoma (ESCC) and its further increase in relapse samples. Upregulation of HSP90 contributes to 5-FU resistance and can predict poor prognosis in cancer patients. Mechanistically, HSP90 K754 is regulated by the cooperation of KAT8 and HDAC11 as the writer and eraser, respectively; SDCBP increases the Kbu level and stability of HSP90 by binding competitively to HDAC11. Furthermore, SDCBP blockade with the lead compound V020-9974 can target HSP90 K754 to overcome 5-FU resistance, constituting a potential therapeutic strategy.